Erbitux cetuximab: Phase III data

In the Phase III EPIC study in about 1,300 patients who were refractory to first-line oxaliplatin-based chemotherapy, Erbitux plus irinotecan missed the primary endpoint of significantly improved overall

Read the full 281 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE